Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
MERMAID-1
Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)
- NCT04385368 ↗
- Completed
- AstraZeneca
- Focused
We haven't built an HCP commentary report on MERMAID-1 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on MERMAID-1 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination With Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (MERMAID-1)
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Durvalumab + SoC chemotherapy; Placebo + SoC chemotherapy
- Arms
- Durvalumab + SoC chemotherapy · Experimental
- Placebo + SoC chemotherapy · Placebo comparator
- Enrollment
- 89
- Primary outcomes
- Disease-free Survival (DFS) in FAS (Using Investigator Assessments According to Response Evaluation Criteria in Solid Tumors 1.1 [RECIST 1.1])
- Sponsor
- AstraZeneca
- Start
- Jul 17, 2020
- Primary completion
- Aug 31, 2023
- Results posted
- Yes
- Registry record
- NCT04385368 · updated Aug 30, 2024